DNA methylation markers and methods of use
The present invention provides methods for identifying metastases by detecting nucleic acid hypermethylation of one or more genes in one or more samples, and in particular in the lymph nodes. The invention further relates to DNA methylation as a predictor of disease recurrence and patient prognosis, specifically in the field of cancer biology.
1. A method for treating non-small cell lung cancer metastases in a human subject consisting of:
a) obtaining a biological sample from a human subject, wherein the biological sample is a lung tumor tissue sample, a regional lymph node or a mediastinal lymph node;
b) isolating genomic DNA from the biological sample;
c) contacting the isolated genomic DNA with bisulfite to transform unmethylated cytosines in the genomic DNA to uracil;
d) PCR amplifying the transformed genomic DNA of the p16 gene encoding SEQ ID NO: 2 and the H-cadherin gene encoding SEQ ID NO: 1 using primers consisting of: (i) a pair of methylation primers specific for p16 and a pair of methylation primers specific for H-cadherin genes and (ii) a pair of unmethylated primers specific for p16 and a pair of unmethylated primers specific for H-cadherin genes;
e) detecting methylation of genomic p16 and H-cadherin DNA;
f) diagnosing non-small cell lung cancer metastases in the human subject; and
g) administering a therapeutically effective amount of a demethylating agent to the human_subject diagnosed as having non-small cell lung cancer metastases, thereby treating the non-small cell lung cancer metastases.
2. The method of claim 1 , wherein the non-small cell lung cancer metastases are micrometastases.
3. A method for treating a recurrence of a non-small cell lung cancer (NSCLC) in a human subject consisting of:
a) obtaining a biological sample from a human subject to be treated, wherein the biological sample is a lung tumor tissue sample, a regional lymph node or a mediastinal lymph node;
b) isolating genomic DNA from the biological sample;
c) contacting the isolated genomic DNA with bisulfite to transform unmethylated cytosines in the genomic DNA to uracil;
d) PCR amplifying the transformed genomic DNA of the p16 gene encoding SEQ ID NO: 2 and the H-cadherin gene encoding SEQ ID NO: 1 using primers consisting of: (i) a pair of methylation primers specific for p16 and a pair of methylation primers specific for H-cadherin genes and (ii) a pair of unmethylated primers specific for p16 and a pair of unmethylated primers specific for H-cadherin genes;
e) detecting methylation of genomic p16 and H-cadherin DNA;
f) diagnosing non-small cell lung cancer metastases in the human subject; and
g) administering a therapeutically effective amount of a demethylating agent to the human_subject diagnosed as having non-small cell lung cancer metastases, thereby treating the recurrence of NSCLC in the human subject.
4. A method for treating recurrence of non-small cell lung cancer (NSCLC) metastases in a human subject consisting of:
a) obtaining a biological sample from a human subject to be treated, wherein the biological sample is a lung tumor tissue sample, a regional lymph node or a mediastinal lymph node;
b) providing a kit having bisulfite and methylation specific PCR primers for detecting a hypermethylation state of a p16 gene encoding SEQ ID NO: 2 and the H-cadherin gene encoding SEQ ID NO: 1;
c) contacting the biological sample with the bisulfite from the kit to transform unmethylated cytosines in the genomic DNA in the biological sample to uracil;
d) PCR amplifying the transformed genomic DNA with the methylation specific PCR primers in the kit to detect nucleic acid methylation of the p16 gene and the H-cadherin gene in the lung tumor tissue sample, a regional lymph node or a mediastinal lymph node in the transformed genomic DNA;
Wherein the methylation specific PCR primers are specific for bisulfite transformed unmethylated cytosines;
e) detecting methylation of genomic p16 and H-cadherin DNA;
f) diagnosing non-small cell lung cancer metastases in the human subject; and
g) administering a therapeutically effective amount of a demethylating agent to the human_subject diagnosed as having non-small cell lung cancer metastases, thereby treating the recurrence of NSCLC in the human subject.